Address
Fraunhoferstrasse 15
Planegg, 82152
Germany
Phone
49 89 864 667 100
Website
Sector
Healthcare
Industry
Biotechnology
Employees
250
First IPO Date
January 04, 2011
| Name | Title | Pay | Year Born |
| Stefan Glombitza | Chief Executive Officer, Chief Operating Officer & Chair of the Executive Board | 612,300 | 1965 |
| Andreas Seidl | Chief Scientific Officer & Member of the Executive Board | 339,500 | 1969 |
| Nicola Mikulcik | Chief Business Officer & Member of the Executive Board | 393,800 | 1971 |
| Enno Spillner | Chief Financial Officer & Member of the Executive Board | 560,900 | 1970 |
| Nicolas Combe | Co-Founder | 0 | N/A |
| Sabrina Muller | Director of Investor Relations & Corporate Communications | 0 | N/A |
| Friedrich-Wilhelm Steinweg | Co-Founder | 0 | N/A |
Headquartered in Planegg, Germany, Formycon AG, founded in 1999 and formerly known as Nanohale AG until 2012, specializes in the development and commercialization of biosimilar medications. Its robust product pipeline includes FYB201, a biosimilar equivalent to Lucentis, which is intended for the treatment of neovascular age-related macular degeneration and other severe eye conditions. The company is also progressing with FYB202, a biosimilar of Stelara, currently undergoing Phase III clinical trials for various inflammatory diseases, including moderate to severe psoriasis, Crohn's disease, and ulcerative colitis. Additionally, FYB203, a biosimilar candidate for Eylea, is in Phase III clinical trials, aiming to address similar ocular diseases like neovascular age-related macular degeneration. Further endeavors include the development of FYB206 and FYB207, with the latter being an antiviral treatment for COVID-19. To ensure the stability of its numerous drug candidates, Formycon AG maintains a collaborative agreement with Leukocare AG.